JPRN-C000000128已完成1 期
A combination phase I/II study of topotecan with carboplatin for relapsed small cell lung cancer - A combination phase I/II study of topotecan with carboplatin for relapsed small cell lung cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria consisted of pulmonary fibrosis or interstitial pneumonitis with symptoms or apparent abnormalities on chest X-ray, massive pleural effusion or ascites, acute inflammation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, severe heart disease, cerebrovascular disease, uncontrollable diabetes mellitus, severe infection.
研究者
相似试验
未知
1 期
A combination phase I study of topotecan with cisplatin for elderly small cell lung cancersmall cell lung cancerJPRN-C000000143Department of Medical Oncology, Kinki University School of Medicine28
尚未招募
1 期
Reducing systemic inflammation in cancer patients with COVID-19 using Topotecan with Dexamethasone and RemdesivirCTRI/2021/03/031969ational University Cancer Institute of Singapore NCIS National University Hospital Singapore
尚未招募
1 期
Reducing hypoxia in patients with COVID-19 using Topotecan with standard of careCTRI/2021/08/035537ational University Cancer Institute of Singapore NCIS National University Hospital Singapore
进行中（未招募）
1 期
Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder TubenkarzinomHECTOR (Hycamtin plus Carboplatin versus Established Regimens for the Treatment of Ovarian Cancer Relapse)Patientinnen mit epithelialem Ovarialkarzinom, Peritoneal- oder Tubenkarzinom und Rezidiv / Progress = 6 Monate nach Ende einer platinhaltigen Primär- oder Sekundärtherapie und Taxan in einer der VortherapienEUCTR2006-004628-34-ATCharité - Universitätsmedizin Berlin550
进行中（未招募）
不适用
HECTORPatientinnen mit epithelialem Ovarialkarzinom, Peritoneal- oder Tubenkarzinom und Rezidiv / Progress = 6 Monate nach Ende einer platinhaltigen Primär- oder Sekundärtherapie und Taxan in einer der VortherapienEUCTR2006-004628-34-DECharité - Universitätsmedizin Berlin550